AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $293.49 billion. The enterprise value is $319.92 billion.
| Market Cap | 293.49B |
| Enterprise Value | 319.92B |
Important Dates
The next estimated earnings date is Tuesday, July 28, 2026, before market open.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 65.41% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 28.25 and the forward PE ratio is 17.78.
| PE Ratio | 28.25 |
| Forward PE | 17.78 |
| PS Ratio | 4.86 |
| Forward PS | 4.60 |
| PB Ratio | 6.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.99 |
| P/OCF Ratio | 20.64 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.98, with an EV/FCF ratio of 28.33.
| EV / Earnings | 30.79 |
| EV / Sales | 5.29 |
| EV / EBITDA | 15.98 |
| EV / EBIT | 21.39 |
| EV / FCF | 28.33 |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.91 |
| Quick Ratio | 0.70 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 1.67 |
| Debt / FCF | 3.01 |
| Interest Coverage | 10.61 |
Financial Efficiency
Return on equity (ROE) is 23.48% and return on invested capital (ROIC) is 16.44%.
| Return on Equity (ROE) | 23.48% |
| Return on Assets (ROA) | 8.49% |
| Return on Invested Capital (ROIC) | 16.44% |
| Return on Capital Employed (ROCE) | 18.36% |
| Weighted Average Cost of Capital (WACC) | 5.21% |
| Revenue Per Employee | $635,531 |
| Profits Per Employee | $109,243 |
| Employee Count | 95,100 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.80 |
Taxes
In the past 12 months, AstraZeneca has paid $2.52 billion in taxes.
| Income Tax | 2.52B |
| Effective Tax Rate | 19.52% |
Stock Price Statistics
The stock price has increased by +28.87% in the last 52 weeks. The beta is 0.21, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +28.87% |
| 50-Day Moving Average | 185.04 |
| 200-Day Moving Average | 181.99 |
| Relative Strength Index (RSI) | 58.77 |
| Average Volume (20 Days) | 2,015,800 |
Short Selling Information
The latest short interest is 1.72 million, so 0.11% of the outstanding shares have been sold short.
| Short Interest | 1.72M |
| Short Previous Month | 1.83M |
| Short % of Shares Out | 0.11% |
| Short % of Float | 0.11% |
| Short Ratio (days to cover) | 0.88 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $60.44 billion and earned $10.39 billion in profits. Earnings per share was $6.64.
| Revenue | 60.44B |
| Gross Profit | 49.26B |
| Operating Income | 14.96B |
| Pretax Income | 12.91B |
| Net Income | 10.39B |
| EBITDA | 20.03B |
| EBIT | 14.96B |
| Earnings Per Share (EPS) | $6.64 |
Balance Sheet
The company has $7.68 billion in cash and $34.03 billion in debt, giving a net cash position of -$26.35 billion or -$17.01 per share.
| Cash & Cash Equivalents | 7.68B |
| Total Debt | 34.03B |
| Net Cash | -26.35B |
| Net Cash Per Share | -$17.01 |
| Equity (Book Value) | 47.38B |
| Book Value Per Share | 30.56 |
| Working Capital | -2.96B |
Cash Flow
In the last 12 months, operating cash flow was $14.22 billion and capital expenditures -$2.93 billion, giving a free cash flow of $11.29 billion.
| Operating Cash Flow | 14.22B |
| Capital Expenditures | -2.93B |
| Depreciation & Amortization | 5.07B |
| Net Borrowing | 1.19B |
| Free Cash Flow | 11.29B |
| FCF Per Share | $7.29 |
Margins
Gross margin is 81.51%, with operating and profit margins of 24.75% and 17.19%.
| Gross Margin | 81.51% |
| Operating Margin | 24.75% |
| Pretax Margin | 21.37% |
| Profit Margin | 17.19% |
| EBITDA Margin | 33.13% |
| EBIT Margin | 24.75% |
| FCF Margin | 18.68% |
Dividends & Yields
This stock pays an annual dividend of $3.20, which amounts to a dividend yield of 1.70%.
| Dividend Per Share | $3.20 |
| Dividend Yield | 1.70% |
| Dividend Growth (YoY) | 3.23% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 48.19% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 1.78% |
| Earnings Yield | 3.54% |
| FCF Yield | 3.85% |
Analyst Forecast
The average price target for AstraZeneca is $224.49, which is 19.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $224.49 |
| Price Target Difference | 19.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 6.80% |
| EPS Growth Forecast (3Y) | 12.15% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.35 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 7 |